WA
LGND icon

Westfuller Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Westfuller Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.21K Hold
13
– – ﹤0.01% 599
2026
Q1 		$2.66K Sell
13
-3
-19% -$594 ﹤0.01% 608
2025
Q4 		$3.02K Hold
16
– – ﹤0.01% 617
2025
Q3 		$2.83K Buy
+16
New +$2.38K ﹤0.01% 599

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Westfuller Advisors's LGND Position: Q2 2026 in Review

Westfuller Advisors held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 13 shares worth $4.21K. The position accounts for ﹤0.01% of the portfolio, ranked #599.

Westfuller Advisors first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Westfuller Advisors held 13 shares of Ligand Pharmaceuticals worth $4.21K as of Q2 2026.
  • Westfuller Advisors left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Westfuller Advisors's portfolio in Q2 2026, its #599 holding.
  • Westfuller Advisors first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Westfuller Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.